Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
Top Cited Papers
- 15 July 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (2) , 787-788
- https://doi.org/10.1182/blood-2007-02-076034
Abstract
To the editor: Patients with immunoglobulin light chain (AL) amyloidosis with cardiac or multiorgan involvement are at high risk of death during or immediately after chemotherapy with intravenous melphalan and autologous stem cell transplantation (ASCT), which is considered the most effectiveKeywords
This publication has 6 references indexed in Scilit:
- Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients with AL (Primary) Amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM Intergroup).Blood, 2005
- The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)Blood, 2005
- Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateBone Marrow Transplantation, 2004
- The role of PBSCT in treatment of AL amyloidosis is far from settledBlood, 2004
- Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationBlood, 2004
- High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year StudyAnnals of Internal Medicine, 2004